Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00230529
Status:
COMPLETED
Last Update Posted:
2011-06-09
First Post:
2005-09-29
Brief Title:
A Safety and Efficacy Study of Infliximab Remicade in Patients With Plaque Type Psoriasis
Sponsor:
Centocor Inc
Organization:
Centocor Inc
Study Overview
Official Title:
A Phase II Multicenter Randomized Double-blind Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab REMICADE Induction Therapy in Patients With Plaque-type Psoriasis
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the effectiveness and safety of infliximab Remicade in patients with plaque-type psoriasis
Detailed Description:
The purpose of this study is to investigate the safety and possible usefulness of infliximab therapy for patients with severe plaque psoriasis In a previous small study of infliximab in 33 patients with psoriasis about 80 of patients treated with infliximab showed improvement in their psoriasis symptoms after the first 3 infusions while 20 of patients who received placebo showed improvement The patients will receive infusions of infliximab either 3 or 5 mgkg or placebo at weeks 026 Patients who have significant psoriasis at week 26 will receive an additional infusion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None